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The microbial world, since its origin, has conducted count-
less genetic experiments to better ensure adaptation and
hence survival in its biologic niche. Through this trial and
error process, “smart” parasites have learned that the ability
to persistently infect without limiting the host’s survival
ensures their own survival. The host is spared immediate
demise, but we are just beginning to understand the long-
term consequences that arise from chronic infections. Sig-
nificant causes of morbidity and mortality not previously
thought to have an infectious etiology (e.g., cancer and heart
disease) are being associated with the residual effects of
chronic infections that may have existed unnoticed for years.
Thus, attaining a more complete understanding of the
mechanisms and potential outcomes of this situation as-
sumes primary importance.
In recent years, much evidence has accumulated that
implicates chronic infection and inflammation in the etiol-
ogy of atherosclerosis. Specifically identified infectious
agents include Chlamydia pneumoniae, cytomegalovirus,
Porphyromonas gingivalis–caused periodontitis (periodonti-
tis of any etiology is a risk factor) and Helicobacter pylori.
Moreover, chronic inflammatory mediators are believed to
contribute to the atherogenic process—principally,
C-reactive protein (CRP), proinflammatory cytokines and
various growth factors (1,2). A direct link between infection
and atherosclerosis has not been rapidly forthcoming, al-
though several proposed mechanisms have been supported
experimentally. One hypothesis proposes direct vascular
invasion. Indeed, chlamydial organisms have been identified
in atheromatous plaque and have also been observed in the
endothelium and smooth muscle of affected vessels (3,4).
However, for those organisms that do not directly invade
the vessel wall, an alternative pathologic mechanism must
exist. Systemic inflammatory mediators may arise in re-
sponse to infections at distant sites, but nonetheless pro-
mote coronary or carotid plaque development. Consistent
with this hypothesis, inflammatory mediators have marked
atherogenic effects on endothelium (5), and these effects are
augmented within preexisting plaque (6). Thus, it appears
probable that some infectious agents contribute to disease
by maintaining a heightened state of inflammatory re-
sponse.
Infection produces a large array of mediators capable of
initiating and maintaining the inflammatory/immune re-
sponse. Not least among these are the products of the
microbes themselves. Unmethylated bacterial deoxyribonu-
cleic acid containing the CpG motif is a potent immuno-
stimulant (7); bacterial heat-shock proteins (HSP) can
activate macrophages (8) and also stimulate the production
of antibodies. These antibodies frequently cross-react with
human HSP and are often invoked as etiologic in autoim-
mune or autoimmune-like conditions. However, the proto-
typical inflammatory bacterial product is endotoxin. Endo-
toxins possess a multitude of biologic effects—most notably,
the initiation of a proinflammatory cascade subsequent to
binding its specific receptor (CD14) on macrophages. This
interaction stimulates the production and release of tumor
necrosis factor (TNF)-alpha, interleukin (IL)-1, IL-6, IL-8,
IL-12, migration inhibitory factor, chemokines, interferon,
eicosanoids and reactive oxygen intermediates (9,10). These
macrophage mediators, in turn, stimulate the production of
a second wave of chemokines, cytokines, adhesion molecules
and signal molecules in a variety of cell types. Among these
are intercellular adhesion molecule, vascular cell adhesion
molecule-1, nitric oxide and acute-phase reactants (CRP,
serum amyloid A). Thus, endotoxin is one of the most
potent biologic response modifiers currently recognized.
In view of the association between inflammation and
atherosclerosis and the potent inflammatory potential of
endotoxin, it is surprising that the contribution of endotoxin
to atherogenesis has received little attention to date. In this
issue of JACC, Wiedermann et al. (11) report on a carefully
conducted and executed prospective study in which they
assessed the patient’s risk of developing atherosclerosis as a
function of baseline endotoxemia. For the study sample of
516 patients, these investigators found a median plasma
endotoxin value of 14 pg/ml. The authors hasten to caution
that the absolute plasma concentrations may be somewhat
misleading in that there may be method- and laboratory-
dependent variability in values. Indeed, a similar study (12)
reported a median of 6 pg/ml with only 2.5% of specimens
falling above 17 pg/ml. To extend the applicability of their
findings to other laboratories, these investigators collapsed
the data into deciles for analysis. Employing this method,
they observed a clear association between endotoxin levels
.50 pg/ml (90th percentile) and newly developing carotid
atherosclerosis among patients available for follow-up
(n 5 466). Their findings were similar for coronary artery
atherosclerosis.
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Although the data presented in Wiedermann et al.’s
report clearly identify that the risk for atherosclerosis is
associated with elevated (highest decile) endotoxin, it is very
difficult to firmly establish what place endotoxin assumes in
the etiology of this disease. This uncertainty arises from the
inability to discern any trend toward risk at blood levels of
endotoxin below 50 pg/ml and from the apparent lack of
risk (odds ratio 0.96) with elevated endotoxin in the absence
of other risk factors (smoking and infection). Although the
actual number of subjects in this last group is not given, it is
likely that the inability to identify risk among these subjects
may have resulted from a small sample size. Also in this
study, 37% of end point events occurred among subjects
with endotoxin levels ,50 pg/ml. Thus, one could conclude
from the totality of findings that endotoxin is neither
necessary nor sufficient in the pathogenic process. It is
beyond dispute, however, that endotoxin greatly augments
the risk associated with smoking and underlying infection.
What part does endotoxin play in the etiology of athero-
sclerosis? The present study does not identify this function,
but it does provide clues. The study design measures only
baseline endotoxin levels and, therefore, cannot distinguish
between transiently elevated and persistently elevated levels.
One may speculate that only chronically elevated endotoxin
is associated with risk for disease, whereas transient eleva-
tions are not. Within this scheme, transient elevation would
account for those individuals who were in the highest decile
at entry into the study but did not go on to develop disease.
When viewed in this perspective, the study results could be
interpreted to suggest that some chronic conditions (e.g.,
infection or smoking) maintain the level of endotoxin
sufficiently high to promote disease. Alternatively, persis-
tently elevated endotoxin levels may be an indicator of
chronic conditions of sufficient inflammatory potential to
promote disease. These similar models differ only in the
relative contribution of endotoxin itself to the disease
process, and either situation would provide a possible
explanation for the strong effect modification seen between
endotoxin and smoking and/or infection.
With respect to the investigators’ hypothesis, some of the
findings of this study appear paradoxical: some individuals
with elevated endotoxin remained disease-free, whereas
decreased plasma endotoxin was not necessarily protective.
There was also a surprising absence of trend toward risk
among subjects with baseline endotoxin levels ,50 pg/ml.
Thus, the relation between endotoxin and vascular disease
appears more complex than expected. The ability for endo-
toxin to promote disease may depend on its ability to initiate
an inflammatory response. This effect may be controlled by
additional regulatory factors. Under certain conditions,
modifying factors could minimize the deleterious effects of
high endotoxin but, conversely, could also augment the
pathogenic effects of lower levels. Factors that negatively
modify the effects of endotoxin are known. For example, the
inflammatory effects of endotoxin are blocked by the cyto-
kine IL-10 (13) and antioxidants (14). In contrast, the
inflammatory potential of endotoxin present in small quan-
tities is augmented by lipopolysaccharide binding protein
(15,16). Modifying factors also regulate the availability and
action of downstream effector molecules (e.g., TNF-alpha,
IL-1, IL-6) in the inflammatory cascade. Future studies will
need to address not only the presence and quantity of
endotoxin, but also its potential to produce inflammation
and, ultimately, vascular disease.
It is of interest to compare the findings of Wiedermann et
al. (11) with those of Ridker et al. (17) in a widely cited
study measuring the risk for acute ischemic events associated
with CRP. Similarities between the studies might be ex-
pected in that CRP production by the liver is stimulated by
the proinflammatory cytokines that are upregulated in
response to endotoxin. In the Ridker et al. study, risk was
limited to the upper quartile of CRP values, and there was
a significant trend across all quartiles. In the present study,
risk was also limited to a restricted, albeit smaller subset
(upper 10%) of subjects, but there was no overall trend
toward risk among the remainder of the sample. These
small differences might be explained by differences in study
design (e.g., period of follow-up [five vs. eight years]) or in
the measured end point (incident atherosclerosis vs. isch-
emic event), but may also be biologic in origin. Proinflam-
matory cytokines and hence CRP production are down-
stream events after stimulation of target cells by endotoxin.
There may be additional upstream initiating events inde-
pendent of endotoxin that nonetheless increase CRP levels
(e.g., immune-mediated inflammation, gram-positive infec-
tion, bacterial nucleic acids and HSP). Within this model,
endotoxin-associated atherosclerosis would be a subset of all
cases of CRP-associated atherosclerosis. As seen by Wied-
ermann et al. (11), endotoxin was associated with a subset of
newly arising cases of disease that was smaller than the
CRP-related subset found in the study by Ridker et al. (17).
Likewise, within this model, cases of endotoxin-associated
atherosclerosis would predictably be associated with ele-
vated CRP. In the present study, elevated CRP did correlate
with elevated endotoxin. Interestingly, an association be-
tween CRP and smoking has been previously noted (18).
The precise interrelation of all of these variables will require
further investigation.
Given the biologic significance of endotoxin and the
heightened awareness of the contribution of inflammation
to atherosclerosis, a study such as that by Wiedermann et al.
(11) has been long overdue. The stage was set for a very
profound revelation. Unhappily, an unambiguous role for
endotoxin in the pathogenesis of carotid or coronary ath-
erosclerosis was not forthcoming, as is frequently the case in
biology. The authors convincingly demonstrate risk for
disease associated with endotoxin; however, the indepen-
dent contributions to disease and pathogenic mechanism(s)
of this substance remain elusive. This study has provided a
needed point of departure for future investigations into this
relation; further investigation will need to address the
long-term contribution of small quantities of endotoxin to
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disease etiology, the correlation between endotoxin and
inflammatory mediators, the effects of modifying factors on
the effects of endotoxin and possibly the ability to thera-
peutically modify its deleterious effects. Based on this and
other studies, it is clear that endotoxin will take its place
among other significant risk factors for atherosclerosis.
It is unlikely that the human population will be able to
easily rid itself of its microbial burden. In contrast, the list
of agents that chronically infect humans continues to grow,
as does the spectrum of complications that arise from such
infections. The challenge to medical science in the coming
years will be to identify the factors that give rise to the array
of effects that chronic infections impart. There are many
pieces in this complex puzzle—some seen but many, as yet,
unseen. Hopefully in the near future we will bring to light
all of the presently hidden contributors to atherosclerosis. A
complete understanding of all of the etiologic processes will
provide avenues to prevention and cure. Or, stated more
simply: what ceases to be a phantom, ceases to be a menace.
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